206 related articles for article (PubMed ID: 16462425)
1. Raloxifene reduces fractures in postmenopausal women with osteoporosis.
Reginster JY; Devogelaer JP
Clin Orthop Relat Res; 2006 Feb; 443():48-54. PubMed ID: 16462425
[TBL] [Abstract][Full Text] [Related]
2. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
3. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of osteoporosis in women with breast cancer.
Mincey BA; Moraghan TJ; Perez EA
Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
6. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
7. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
8. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
9. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis.
Burlet N; Reginster JY
Clin Orthop Relat Res; 2006 Feb; 443():55-60. PubMed ID: 16462426
[TBL] [Abstract][Full Text] [Related]
10. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene use in clinical practice: efficacy and safety.
Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene therapy in the reduction of fractures.
Cefalu CA
Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
[No Abstract] [Full Text] [Related]
13. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
Cranney A; Adachi JD
Drug Saf; 2005; 28(8):721-30. PubMed ID: 16048357
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic prevention of osteoporotic fractures.
Zizic TM
Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
[TBL] [Abstract][Full Text] [Related]
15. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial.
Silverman SL; Christiansen C; Genant HK; Vukicevic S; Zanchetta JR; de Villiers TJ; Constantine GD; Chines AA
J Bone Miner Res; 2008 Dec; 23(12):1923-34. PubMed ID: 18665787
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL
Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene: new preparation. Not better than oestrogen.
Prescrire Int; 1999 Dec; 8(44):165-7. PubMed ID: 11503811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]